Posted by Michael Wonder on 07 Sep 2022
Seres Therapeutics announces completion of rolling BLA submission to FDA for investigational microbiome therapeutic SER-109 for recurrent C. difficile infection
7 September 2022 - Investigational therapeutic SER-109 has the potential to become the first-ever FDA approved oral microbiome therapeutic.
Seres Therapeutics today announced it has completed the rolling submission process for its biologics license application to the US FDA for SER-109 for the prevention of recurrent C. difficile infection.
